Showing results (261-270 of 313) with videos related to

Sort By:
Pageof 32
Antimicrobial Agents and Chemotherapy|December 27, 2005
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignanciesGloria N Mattiuzzi, Gladys Alvarado, Francis J Giles, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Blood|October 7, 2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBob Löwenberg, Petra Muus, Gert Ossenkoppele, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Investigational New Drugs|January 22, 2010
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemiaIsam Abdel-Karim, William K Plunkett, Susan O'Brien, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
Blood|June 29, 2007
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano, Hui Yang, Stefan Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Pageof 32